Metabolic and Reproductive Outcomes of Combined GLP-1 Receptor Agonist and Metformin Therapy in Polycystic Ovary Syndrome: A Systematic Review of Comparative Studies
SN Comprehensive Clinical Medicine · 05.11.2026 · 8 (1)
DOI: 10.1007/s42399-026-02855-1 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Emmanuel Oyedeji Oyetola und 7 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Polycystic ovary syndrome (PCOS) affects about 20% of women of reproductive age, leading to hyperandrogenism, insulin resistance and ovulatory dysfunction with significant metabolic and reproductive consequences. Although metformin improves insulin sensitivity, its weight loss effects are modest. GLP-1 receptor agonist (GLP-1 RAs) enhances satiety and glycemic control, prompting interest in their combination for the management of PCOS.
Objective
This systematic review evaluated the metabolic and reproductive outcomes of combined use of a GLP-1 RA and metformin against metformin monotherapy in women with Polycystic ovary syndrome.
Methods
Following PRISMA 2020 guidelines, comprehensive searches were conducted in PubMed, Embase, and Cochrane Library. Randomized controlled trials comparing combined GLP-1 RA and metformin therapy with metformin monotherapy in women with PCOS were included. Eight studies (seven from China, one from Slovenia; published 2014–2025) comprising 40–100 participants met the inclusion criteria. Primary outcomes include anthropometric measures (BMI, weight), metabolic outcomes (regularity of menses, hormonal profile).
Results
Combination therapy yielded better anthropometric improvements (weight loss: 3.8–6.5 kg vs. 1.2–2.5 kg; BMI/WC reductions), metabolic benefits (lower FBG, HOMA-IR, LDL-C/TG higher HDL/SHBG), and reproductive advantage (reduced TT/FAI, menstrual recovery in 72–92% vs. 42%; pregnancy rates increased to 35% vs. 15%). GI side effects are transient and tolerable.
Conclusion
GLP-1 RA and metformin offer synergistic benefits over metformin alone for obese PCOS patients, which supports its role in high-risk cases pending larger trials.
Zitieren
APA
Oyetola, E. O., Jagunmolu, H. A., Adejumo, T. P., Ademoloye, O. I., Antai, D. A., Oyelude, S. O., Akande, D., & Ariyo, O. (2026). Metabolic and Reproductive Outcomes of Combined GLP-1 Receptor Agonist and Metformin Therapy in Polycystic Ovary Syndrome: A Systematic Review of Comparative Studies. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02855-1
Vancouver
Oyetola EO, Jagunmolu HA, Adejumo TP, Ademoloye OI, Antai DA, Oyelude SO, et al. Metabolic and Reproductive Outcomes of Combined GLP-1 Receptor Agonist and Metformin Therapy in Polycystic Ovary Syndrome: A Systematic Review of Comparative Studies. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02855-1
BibTeX
@article{Oyetola2026,
author = {Oyetola, Emmanuel Oyedeji and Jagunmolu, Habiblah Ayomide and Adejumo, Temilade Patience and Ademoloye, Oluwafemi Ibukun and Antai, Dorothy Abimbola and Oyelude, Samuel Oyeponle and Akande, Deborah and Ariyo, Oluwadamilola},
title = {Metabolic and Reproductive Outcomes of Combined GLP-1 Receptor Agonist and Metformin Therapy in Polycystic Ovary Syndrome: A Systematic Review of Comparative Studies},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02855-1}
}
EUVIMED